Form 4: Corcept Therapeutics CEO Joseph Belanoff Reports Stock Sale and Option Grant
SEC Form 4 Filing
CEO Joseph Belanoff reports selling shares and receiving stock options in Corcept Therapeutics.
Summary
- Joseph K. Belanoff, CEO of Corcept Therapeutics, reported a transaction involving the company's stock.
- On March 3, 2025, Belanoff sold 2,924 shares of common stock at a price of $60.909 per share.
- Following the transaction, Belanoff directly owns 3,019,411 shares through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.
- On February 28, 2025, Belanoff was granted stock options to purchase 350,000 shares at an exercise price of $60.58, exercisable ratably over four years.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions. The sale is under a 10b5-1 plan, which mitigates negative interpretations.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- Shareholders may interpret the CEO's stock sale and option grant as a signal, although the pre-arranged trading plan mitigates potential negative interpretations.
Key Dates
| Date | Description |
|---|---|
| 2002-04-29 | Date of the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD |
| 2024-11-26 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-02-28 | Date of stock option grant |
| 2025-02-28 | First date stock options are exercisable |
| 2025-03-03 | Date of stock sale |
| 2035-02-28 | Expiration date of stock options |
| 2025-03-04 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.